Patrick Brady, Vice President for Regulatory Policy & Intelligence at Bayer, discusses the impact of artificial intelligence on clinical and regulatory science professionals. Mr. Brady will moderate the panel discussion Exploring the Use of Artificial Intelligence: Trust in Technology, or Trust in Each Other? at DIA Europe 2018.
Dr. J. Vijay Venkatraman, India Regional Editor for Global Forum and Managing Director & CEO for Oviya MedSafe Private Limited (India), discusses the Pharmacovigilance Guidance Document for Marketing Authorization Holders of Pharmaceutical Products in India, which came into effect January 2018, and the Pharmacovigilance Programme of India (PvPI).
Harmonizing clinical trial assessment and supervision in the EU through the portal and database established by the new EU Clinical Trial Regulation, and maintained by the EMA, is not the only change rippling through clinical trials in Europe, explain Dr. Mireille Muller, Regulatory Policy Director for Novartis A-G in Switzerland; and Dr. Greet Musch, Director-General for Pre-Authorisation at the Federal Agency for Medicines and Healthcare Products of Belgium. Dr. Muller and Dr. Musch will help lead discussions on this topic at DIA Europe 2018.
Maryll Toufanian, JD, Acting Director, US FDA Office of Generic Drug Policy, discusses the US FDA’s Drug Competition Action Plan, why US consumers can feel safe taking generic drugs, and how generic drugs can help reduce costs for healthcare patients and systems. Learn more at our Complex Drug-Device Generic Combination Products conference.
The World Health Organization recently estimated that, worldwide, more than 15 million people suffer from opioid dependence and roughly 69,000 people die from opioid overdoses each year. In this Global Forum podcast, Professor Edward Bilsky, an expert in opioid pharmacology and early-stage drug development who serves as the Provost and Chief Academic Officer at Pacific Northwest University of Health Sciences, discusses the importance of patient engagement in opioid pain management.
Dr. Ellen V. Sigal, Chairperson and Founder of Friends of Cancer Research, discusses the advocacy organization’s role in the Breakthrough Therapy designation in this Global Forum podcast. Dr. Sigal is also Chair of the Board of Directors of the Reagan-Udall Foundation, serves on the Board of the Foundation for the National Institutes of Health, and serves on the Cancer Moonshot Blue Ribbon Panel established by Vice President Joe Biden.
In this Global Forum podcast, Dr. Julie Gerberding (Chief Patient Officer and Executive Vice President for Policy, Communications, and Population Health, Merck) discusses the evolution of patient engagement and her service as former Director for the US Centers for Disease Control and Prevention, as an executive sponsor of the Merck Women’s Network, and as honorary co-chair for DIA Global 2018 in Boston.
Today’s patients can get involved at either end of the “bench to bedside” cycle, explain Christopher McCabe, Executive Director and CEO, Institute of Health Economics (Canada), and Dimitrios Athanasiou, board member of United Parent Projects Muscular Dystrophy and patient representative to EURORDIS, who will also help guide patient engagement discussions at DIA Europe 2018.
Processes to better determine a medicine’s value are discussed by Dr. Indranil Bagchi, Vice President, Value and Access, Novartis Oncology, and Dr. Thomas Szucs, Professor of Pharmaceutical Medicine and Director of the European Center of Pharmaceutical Medicine at the University of Basel, who will help lead discussions on value and access at DIA Europe 2018.
Co-author Dr. Jeffrey Sherman, Chief Medical Officer / Executive Vice President at Horizon Pharmaceuticals, and DIA’s liaison to the Clinical Trials Transformation Initiative, reviews The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials with Ron Bartek, Co-Founder and President of the Friedreich’s Ataxia Research Alliance.